ReviewCancer treatment and research2026
The Warburg Effect and Aerobic Glycolysis in Tumors.
Review in Cancer treatment and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A basic metabolic characteristic of carcinogenesis, namely the Warburg effect, is defined by the preferred utilization of aerobic glycolysis for energy generation in cancer cells, even in the presence of oxygen. Here, rapid proliferation and carefully planned adaptation to fulfill biosynthetic, redox, and survival requirements of malignant transformation are byproducts due to this adjustment in energy metabolism. Aerobic glycolysis enables tumor cells to accumulate metabolic intermediates, i.e., essential for macromolecular synthesis, supports redox homeostasis through NADPH production, and modulates tumor microenvironment via acidifying extracellular pH. Thereby, it leads to the promotion of invasion and immune evasion. Further, the discovery of this phenomenon by Otto Warburg nearly a century ago laid the foundation for modern cancer metabolism research. Advances in molecular oncology have since elucidated the regulatory role of oncogenes (such as MYC, RAS, and PI3K), tumor suppressors (like p53 and LKB1), and transcriptional networks (e.g., HIF-1α) to enforce glycolytic dependency. Recent studies further highlight that the Warburg effect integrates with mitochondrial signaling, epigenetic modifications, and metabolic cross talk between cancer cells as well as stromal components to provide novel therapeutic opportunities. This book chapter explores biochemical, molecular, and physiological dimensions of the Warburg effect along with its mechanistic basis, role in tumor progression, and emerging strategies to exploit glycolytic addiction in cancer therapy.
Indexed as
Identifiers
42144518What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.